(window.webpackJsonp=window.webpackJsonp||[]).push([[13],{"+5i3":function(e,t,a){},DWZI:function(e,t,a){"use strict";a.r(t),a.d(t,"query",(function(){return N}));var n=a("q1tI"),r=a.n(n),s=a("XlOV"),c=a("8esB"),o=(a("E5k/"),a("7oih")),l=a("EYWl"),i=a("nGjg"),u=a("oMLz"),d=a("7vrA"),m=a("pBrU"),p=a("arQm"),f=a.n(p),g=a("SG61"),h=a.n(g),b=a("aubv"),v=a.n(b),E=function(e){var t=e.header,a=e.topicsA,n=e.topicsBHeader,s=e.topicsB,c=e.caption1,o=e.caption2;return r.a.createElement(d.a,{id:"design",as:"section",className:v.a.cardContainer},r.a.createElement("h2",{className:v.a.header},t.title,t.references.length>0&&r.a.createElement("sup",{className:v.a.references},t.references.join(","))),r.a.createElement("ul",{className:v.a.topics},a.map((function(e,t){var a=e.content,n=e.references;return r.a.createElement("li",{className:v.a.topic,key:t},a,n.length>0&&r.a.createElement("sup",{className:v.a.references},n.join(",")))}))),r.a.createElement(m.a,null,c.title),r.a.createElement("img",{className:v.a.chart,alt:"",src:f.a}),r.a.createElement("img",{className:v.a.mobileChart,alt:"",src:h.a}),r.a.createElement("h3",{className:v.a.topicsHeader,id:"results"},n.title,n.references.length>0&&r.a.createElement("sup",{className:v.a.references},n.references.join(","))),r.a.createElement("ul",{className:v.a.topics},s.map((function(e,t){var a=e.content;return r.a.createElement("li",{className:v.a.topic,key:t},a)}))),r.a.createElement(m.a,{subtext:o.title},o.header.title,o.header.references.length>0&&r.a.createElement("sup",{className:v.a.references},o.header.references.join(","))),r.a.createElement("p",{className:v.a.footer},"DBPCFC = double-blind, placebo-controlled food challenge; psIgE = peanut-specific immunoglobulin E; RAMSES = ",r.a.createElement("strong",null,"R"),"eal-World"," ",r.a.createElement("strong",null,"A"),"R101 ",r.a.createElement("strong",null,"M"),"arket ",r.a.createElement("strong",null,"S"),"upporting ",r.a.createElement("strong",null,"E"),"xperience ",r.a.createElement("strong",null,"S"),"tudy."))},C=(a("Jb3X"),a("+5i3"),a("mOwP")),y=a.n(C),A=["PALFORZIA [package insert]. Brisbane, CA: Aimmune Therapeutics, Inc","ClinicalTrials.gov website. https://clinicaltrials.gov/ct2/show/NCT03126227. NLM identifier: NCT03126227. February 26, 2018. Accessed September 14, 2020."],N=(t.default=function(e){var t=e.data,a=e.location,n=function(e){var t=e.referencesHeader;return{header:Object.assign({},{title:"RAMSES: A clinical trial for peanut allergy assessing safety",references:[1]}),tabs:[].concat([{label:"Study Design",href:"#design"},{label:"Study Results",href:"#results"}]),cardA:Object.assign({},{header:{title:"RAMSES was a phase 3, multicenter, double-blind, placebo-controlled randomized study",references:[1]},topicsA:[{content:"Designed to gain experience with PALFORZIA in a real-world setting, without requirement of a DBPCFC for study entry",references:[]},{content:"All participants were monitored for adverse events throughout the ≈6-month study duration",references:[1]}],topicsBHeader:{title:"Highly peanut-sensitive participants",references:[1]},topicsB:[{content:"Clinical history of peanut allergy, including onset of symptoms within 2 hours of known oral peanut exposure"},{content:"psIgE of ≥14 kUA/L"},{content:"Mean wheal diameter on skin-prick test ≥8 mm greater than negative control"}],caption1:{title:"Participants were NOT required to complete a DBPCFC for study entry."},caption2:{header:{title:"Primary endpoint",references:[2]},title:"Frequency of treatment-emergent adverse events, including serious adverse events, during the overall study period"},footnotes:"DBPCFC = double-blind, placebo-controlled food challenge; psIgE = peanut-specific immunoglobulin E; RAMSES = Real-World AR101 Market Supporting Experience Study in Peanut-Allergic Children."}),cardB:Object.assign({},{header:{title:"RAMSES study results",references:[]},topics:[{content:"In RAMSES, no treatment-emergent adverse events ≥5% were reported in participants following daily treatment with 300 mg of PALFORZIA (n=265)",references:[1]}],caption:{header:{title:"Primary endpoint",references:[2]},title:"Frequency of treatment-emergent adverse events, including serious adverse events, during the overall study period"}}),referencesHeader:t.title}}(t.page),d=n.header,m=n.tabs,p=n.referencesHeader,f=n.cardA;n.cardB;return r.a.createElement(s.a,{initialState:c.a,reducer:c.b},r.a.createElement(o.a,{showSeeResultsMenu:!0,referencesHeader:p,references:A},r.a.createElement(l.a,{title:t.page.title}),r.a.createElement("main",{className:y.a.content},r.a.createElement(i.a,d),r.a.createElement(u.a,{hash:a.hash,tabs:m}),r.a.createElement(E,f))))},"2040373984")},Jb3X:function(e,t,a){e.exports={cardContainer:"RamsesCardB-module--cardContainer--BRzHV",header:"RamsesCardB-module--header--2uMjb",references:"RamsesCardB-module--references--13bSA",topics:"RamsesCardB-module--topics--2b5zU",topic:"RamsesCardB-module--topic--2gkLv"}},SG61:function(e,t,a){e.exports=a.p+"static/ramses-card-a-mobile-chart-ffab3ce90dc61951297ac13926942beb.svg"},arQm:function(e,t,a){e.exports=a.p+"static/ramses-card-a-desktop-chart-b030487be02ea329da86d2032f95a347.svg"},aubv:function(e,t,a){e.exports={cardContainer:"RamsesCardA-module--cardContainer--CmNv4",header:"RamsesCardA-module--header--2XjqF",references:"RamsesCardA-module--references--2MCq4",topicsHeader:"RamsesCardA-module--topicsHeader--24beG",topics:"RamsesCardA-module--topics--2Sq4_",topic:"RamsesCardA-module--topic--1BjUS",chart:"RamsesCardA-module--chart--1Z2-V",mobileChart:"RamsesCardA-module--mobileChart--vWfEv",footer:"RamsesCardA-module--footer--31-V0"}},cZLO:function(e,t,a){e.exports={tabbedNav:"TabbedNav-module--tabbedNav--2QyRE",link:"TabbedNav-module--link--xnZ18"}},mOwP:function(e,t,a){e.exports={content:"key-studies-ramses-module--content--1mxu0"}},mXzk:function(e,t,a){e.exports={caption:"Caption-module--caption--1NDgl",captionSubtext:"Caption-module--captionSubtext--3qYHf",subtext:"Caption-module--subtext--DTFyX"}},nGjg:function(e,t,a){"use strict";var n=a("q1tI"),r=a.n(n),s=a("7vrA"),c=a("xdkL"),o=a.n(c);t.a=function(e){var t=e.title,a=e.references,n=void 0===a?[]:a;return console.log("references ",n),r.a.createElement(s.a,{fluid:!0,as:"section",className:o.a.pageTitle},r.a.createElement(s.a,null,r.a.createElement("h1",{className:o.a.title},t,n.length>0&&r.a.createElement("sup",{className:o.a.references},n.join(",")))))}},oMLz:function(e,t,a){"use strict";a("y7hu");var n=a("q1tI"),r=a.n(n),s=a("7vrA"),c=a("cZLO"),o=a.n(c);t.a=function(e){var t=e.hash,a=e.tabs,c=e.className,l=void 0===c?"":c,i=function(e){var t=document.querySelector(e);if(t){var a=window.getComputedStyle(t).getPropertyValue("padding-top");a=a.substring(0,a.length-2);var n=t.getBoundingClientRect().top,r=document.getElementById("header").offsetHeight,s=n-r+parseInt(a);console.dir(t),console.log(n),console.log(r),console.log(a),console.log(s),window.scrollTo({top:s,behavior:"smooth"})}};return Object(n.useEffect)((function(){var e;return t&&(e=setTimeout((function(){return i(t)}),1e3)),function(){clearTimeout(e)}}),[t]),r.a.createElement(s.a,{as:"section",className:o.a.tabbedNavContainer+" "+l},r.a.createElement("nav",{className:o.a.tabbedNav},a.map((function(e){var t=e.label,a=e.href;return r.a.createElement("a",{key:t,tabIndex:0,href:""+a,onClick:function(e){window.history.pushState(null,null,a),i(a),e.preventDefault()},className:o.a.link},t)}))))}},pBrU:function(e,t,a){"use strict";var n=a("q1tI"),r=a.n(n),s=a("TSYQ"),c=a.n(s),o=a("mXzk"),l=a.n(o);t.a=function(e){var t,a=e.children,n=e.subtext;return r.a.createElement("summary",{className:c()([l.a.caption],(t={},t[l.a.captionSubtext]=n,t))},a,n&&r.a.createElement("p",{className:l.a.subtext},n))}},xdkL:function(e,t,a){e.exports={title:"PageTitle-module--title--EAYj9",references:"PageTitle-module--references--272vH"}}}]);
//# sourceMappingURL=component---src-pages-ramses-js-05c4e8c3d6cb969e871d.js.map